Technologies
This technology is a multiplex immunofluorescence method using beam-splitting imaging and non-specific antibodies to create a high-throughput, efficient approach for cell type identification.
Conventional immunohistochemistry (IHC) involves labeling a specific cell type with a corresponding fluorophore marker, typically used to image pathological tissue sections for diagnostic testing. There is a significant limitation in the number of cell types that can be recognized by IHC via chromogenic or fluorescent staining methods, as the use of too many fluorophores results in spectral overlap. Recent multiplex immunofluorescence (mIF) methods have enabled the simultaneous detection of multiple cells, but remain limited by cross-interference of intermediate immunostaining antibodies, labor-intensive processes, and prolonged imaging time.
This technology is a multiplex immunochemistry/immunofluorescence approach that utilizes an associated beam-splitting imaging technique and non-specific antibodies to create combinations of fluorophore signals, thereby maximizing cell type recognition. By utilizing multiple primary antibodies for a specific fluorophore-binding secondary antibody, the potential number of identifiable cell types increases exponentially through this “combinatorial coding” approach. The 4-way spectral image splitter further enables simultaneous imaging of 4 colors with minimal aberrations. As such, this technology is ideal for high-throughput and efficient multi-cell and tissue assay, diagnostic, and drug discovery platforms.
Elizabeth M. C. Hillman, Ph.D.
Patent Pending (US20250284135)
IR CU23161
Licensing Contact: Kristin Neuman